Undecimal Bio
Cambridge, United Kingdom
◆ About Undecimal Bio
AI-enabled platform for RNA medicine delivery beyond the liver using combinatorial chemistry and transformer-based AI.
◆ What sets it apart
Its DELiveri platform combines massive combinatorial ligand libraries, single-molecule-resolution functional delivery readouts, and AI-derived structure-activity models to discover molecules that achieve productive intracellular delivery beyond the liver.[1][2][7]
◆ Sectors
◆ Business
Modeltransactional
CustomerPharmaceutical and biotechnology companies developing RNA or siRNA therapeutics
◆ Notable
- Launched as a spin-out from Eleven Therapeutics with an oversubscribed $18 million seed financing.[1][2][8]
- Developed DELiveri to identify conjugates for targeted siRNA delivery beyond the liver.[1][7]
- Established initial programs focused on renovascular disease, kidney, and vascular-system applications.[1][7]
◆ Funding rounds
◆ Explore the market
◆ FAQ
What does Undecimal Bio do?
AI-enabled platform for RNA medicine delivery beyond the liver using combinatorial chemistry and transformer-based AI.
Where is Undecimal Bio based?
Undecimal Bio is based in Cambridge, United Kingdom, founded in 2026.
How much has Undecimal Bio raised?
Undecimal Bio has raised $18M in tracked funding and is currently at the seed stage.
Who has invested in Undecimal Bio?
Investors in Undecimal Bio include 4BIO Capital, IQ Capital, Verve Ventures, Harel Tech, Entrée Capital, Kerna Ventures and Saras Capital.